The Impact of Diabetes Mellitus on Hepatocellular Carcinoma Development

Birupaksha; Angel; Arohi; Jotishko; Girraj

doi:10.25163/health.3110235

Epidemiology and public health

REVIEWS (Open Access)

Previous Next Contents Vol 3 (1)

The Impact of Diabetes Mellitus on Hepatocellular Carcinoma Development

Birupaksha Biswas¹, Angel Saluja¹, Arohi Singh¹, Jotishko Biswas², Girraj Dhakad³

+ Author Affiliations

Clinical Epidemiology & Public Health 3 (1) 1-8 https://doi.org/10.25163/health.3110235

Submitted: 01 March 2025 Revised: 06 May 2025 Published: 08 May 2025

Abstract

Background: The metabolic disorder Diabetes mellitus constitutes a steadily increasing global health problem which produces multiple complications during its progressive course. New epidemiological studies indicate that diabetes mellitus (DM) leads to hepatocellular carcinoma (HCC) development which ranks as the sixth most common cancer type and presents as one of the most frequent cancer-related fatalities. HCC development results from three main factors which link diabetes mellitus to the disease including insulin resistance, chronic inflammation, hyperglycemia and obesity. Methods: This evaluation will consider research from several populations using case-control studies and cohort studies as well as meta-analyses to explore the molecular pathways between DM and HCC while determining the impact of drinking alcohol and viral hepatitis risks to DM patients. Results: We will analyze how antidiabetic medications affect the risk of HCC development in the final part. The risk of developing HCC is doubled to tripled for subjects with diabetes mellitus according to epidemiologic research. The combination of high blood sugar levels creates inflammation alongside oxidative stress but elevated insulin levels coupled with long-running triggers of insulin-like growth factor 1 activity stimulates new liver cell growth. Some studies show that diabetes mellitus increases HCC development risk mainly when hepatitis B and C infections simultaneously occur. The independent risk factor status of diabetes mellitus exists for the development of HCC regardless of additional liver diseases. Conclusion: Current research remains limited about the HCC developmental effects of weight variations caused by antidiabetic medications alongside diabetes mellitus history.

Keywords: Hepatocellular carcinoma, diabetes mellitus, hyperglycemia, chronic inflammation, metabolic dysregulation.

References

Arnold, R., Issar, T., Krishnan, A. V., & Pussell, B. A. (2016). Neurological complications in chronic kidney disease. JRSM Cardiovascular Disease, 5. https://doi.org/10.1177/2048004016677687

Aggarwal, G., Kamada, P., & Chari, S. T. (2012). Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas, 42(2), 198–201. https://doi.org/10.1097/mpa.0b013e3182592c96

Akter, T., Ali, M. R., Faruquee, M. N. A., Bashir, M. S., Rahaman, S., Rahman, M. A., & Islam, S. (2024). A comprehensive study of hepatitis B infections in Bangladesh: Epidemiology, risk factors, and clinical-laboratory correlations. Viral Infections and Cancer Research, 1(1), 8426. https://doi.org/10.59429/vicr.v1i1.8426

Bashir, M. S., Hossian, M., Uddin, M. K. M., Sayem, M. A., Sultana, A., Rana, F. A., Akter, T., Das, N., Rana, M. S., & Das, S. S. (2025). Association between hepatocellular carcinoma and diabetes mellitus. Journal of Primeasia, 6(1), 1–7. https://doi.org/10.25163/primeasia.6110193

Bashir, M. S., Sayem, M. A., Das, S. S., Das, N., Sultana, A., Rahman, M. M., Shamsuzzaman, M., Paul, P., Hossian, M., & Uddin, M. K. M. (2025). High viral load is a risk factor for hepatocellular carcinoma: Clinical and laboratory insights from a cross-sectional study. Journal of Angiotherapy, 9(1), 1–8. https://doi.org/10.25163/angiotherapy.9110219

Beasley, P. R. (2006b). Diabetes and hepatocellular carcinoma. Hepatology, 44(6), 1408–1410. https://doi.org/10.1002/hep.21430

Chen, C., Yu, M., & Liaw, Y. (1997). Epidemiological characteristics and risk factors of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 12(9–10). https://doi.org/10.1111/j.1440-1746.1997.tb00513.x

Campbell, C., Wang, T., McNaughton, A. L., Barnes, E., & Matthews, P. C. (2020). Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. Journal of Viral Hepatitis, 28(3), 493–507. https://doi.org/10.1111/jvh.13452

Das, S. S., Hossain, M. S., Sultana, A., Rana, F. A., Hossen, A., Maowla, M. S., Uddin, M. K. M., Sayem, M. A., Hossian, M., & Bashir, M. S. (2025). The influence of chronic kidney disease on hepatocellular carcinoma. Journal of Primeasia, 6(1), 1–8. https://doi.org/10.25163/primeasia.6110204

De Cól, J. P., De Lima, E. P., Pompeu, F. M., Araújo, A. C., De Alvares Goulart, R., Bechara, M. D., Laurindo, L. F., Méndez-Sánchez, N., & Barbalho, S. M. (2024). Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. International Journal of Molecular Sciences, 25(7), 3694. https://doi.org/10.3390/ijms25073694

Dyal, H. K., Aguilar, M., Bartos, G., Holt, E. W., Bhuket, T., Liu, B., Cheung, R., & Wong, R. J. (2015). Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Digestive Diseases and Sciences, 61(2), 636–645. https://doi.org/10.1007/s10620-015-3983-3

El–Serag, H. B., Hampel, H., & Javadi, F. (2006). The association between diabetes and hepatocellular carcinoma: A Systematic Review of Epidemiologic evidence. Clinical Gastroenterology and Hepatology, 4(3), 369–380. https://doi.org/10.1016/j.cgh.2005.12.007

Fujita, K., Iwama, H., Miyoshi, H., Tani, J., Oura, K., Tadokoro, T., Sakamoto, T., Nomura, T., Morishita, A., Yoneyama, H., & Masaki, T. (2016). Diabetes mellitus and metformin in hepatocellular carcinoma. World Journal of Gastroenterology, 22(27), 6100. https://doi.org/10.3748/wjg.v22.i27.6100

Harding, J. L., Weber, M. B., & Shaw, J. E. (2024). The Global Burden of Diabetes. Textbook of Diabetes, 28–40. https://doi.org/10.1002/9781119697473.ch3

Hassan, M. M., Hwang, L., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002c). Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36(5), 1206–1213. https://doi.org/10.1053/jhep.2002.36780

Hossian, M., Hasan, M. M., Sultana, A., Das, S. S., Paul, P., Shamsuzzaman, M., Rahman, M. M., Uddin, M. K. M., Sayem, M. A., & Bashir, M. S. (2024). Potential role of Helicobacter pylori infection in hepatocellular carcinoma: A clinical and laboratory-based study. Journal of Angiotherapy, 8(12), 1–9. https://doi.org/10.25163/angiotherapy.81210217

Hassan, M. M., Hwang, L., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002b). Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36(5), 1206–1213. https://doi.org/10.1053/jhep.2002.36780

Islam, M. R., Yesmin, T., Prapty, A. N., Biswash, M. A. R., Rana, M. S., & Rashid, M. H. O. (2024). Natural environmental sources of resveratrol and its therapeutic role in cancer prevention. Australian Herbal Insight, 7(1), 1–11. https://doi.org/10.25163/ahi.719931

Kuo, C., Grainge, M. J., See, L., Yu, K., Luo, S., Zhang, W., & Doherty, M. (2015). Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Research & Therapy, 17(1). https://doi.org/10.1186/s13075-015-0522-8

Kinoshita, Y., Adachi, K., Hongo, M., & Haruma, K. (2011). Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. Journal of Gastroenterology, 46(9), 1092–1103. https://doi.org/10.1007/s00535-011-0429-3

Li, X., Wang, X., & Gao, P. (2017c). Diabetes mellitus and risk of hepatocellular carcinoma. BioMed Research International, 2017, 1–10. https://doi.org/10.1155/2017/5202684

Mekala, K. C., & Bertoni, A. G. (2019). Epidemiology of diabetes mellitus. In Elsevier eBooks (pp. 49–58). https://doi.org/10.1016/b978-0-12-814833-4.00004-6

Mantovani, A., & Targher, G. (2017). Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Annals of Translational Medicine, 5(13), 270. https://doi.org/10.21037/atm.2017.04.41

Nawaz, R., Zahid, S., Idrees, M., Rafique, S., Shahid, M., Ahad, A., Amin, I., Almas, I., & Afzal, S. (2017). HCV-induced regulatory alterations of IL-1β, IL-6, TNF-α, and IFN-ϒ operative, leading liver en-route to non-alcoholic steatohepatitis. Inflammation Research, 66(6), 477–486. https://doi.org/10.1007/s00011-017-1029-3

Ozakyol, A. (2017). Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). Journal of Gastrointestinal Cancer, 48(3), 238–240. https://doi.org/10.1007/s12029-017-9959-0

Reeves, H. L., Zaki, M. Y. W., & Day, C. P. (2016). Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD. Digestive Diseases and Sciences, 61(5), 1234–1245. https://doi.org/10.1007/s10620-016-4085-6

Rana, M. S., Bashir, M. S., Das, S. S., Hossain, M., & Barua, S. (2024). Biomarkers for hepatocellular carcinoma: Diagnosis, prognosis, and treatment response assessment – A systematic review. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519784

Ruhl, C. E., & Everhart, J. E. (2003c). Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology, 124(1), 71–79. https://doi.org/10.1053/gast.2003.50004

Shi, T., Kobara, H., Oura, K., & Masaki, T. (2021). Mechanisms Underlying Hepatocellular Carcinoma Progression in Patients with Type 2 Diabetes. Journal of Hepatocellular Carcinoma, Volume 8, 45–55. https://doi.org/10.2147/jhc.s274933

Salam, M. T., Mou, M. A., et al. (2024). Assessment of lipid profile in hepatocellular carcinoma patients: A prospective study in Bangladesh. Journal of Primeasia, 5(1), 1–8. https://doi.org/10.25163/primeasia.519787

Sagnelli, E., Macera, M., Russo, A., Coppola, N., & Sagnelli, C. (2019). Epidemiological and etiological variations in hepatocellular carcinoma. Infection, 48(1), 7–17. https://doi.org/10.1007/s15010-019-01345-y

Singh, M. K., Das, B. K., Choudhary, S., Gupta, D., & Patil, U. K. (2018). Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomedicine & Pharmacotherapy, 106, 991–1002. https://doi.org/10.1016/j.biopha.2018.06.095

Tufael, M., Rahman, M. M., Upadhye, V. J., Hossain, M. F., & Uddin, N. (2024). Combined biomarkers for early diagnosis of hepatocellular carcinoma. Journal of Angiotherapy, 8(5), 1–12. https://doi.org/10.25163/angiotherapy.859665

Tufael, M., Kar, A., Rashid, M. H. O., Sunny, A. R., Raposo, A., Islam, M. S., Hussain, M. A., Hussen, M. A., Han, H., Coutinho, H. D. M., Ullah, M. S., & Rahman, M. M. (2024). Diagnostic efficacy of tumor markers AFP, CA19-9, and CEA in hepatocellular carcinoma patients. Journal of Angiotherapy, 8(4), 1–10. https://doi.org/10.25163/angiotherapy.849513

Uddin, M. K. M., Sultana, A., Rahman, M. M., Shamsuzzaman, M., Paul, P., Hasan, M. M., Sayem, M. A., Bashir, M. S., Das, S. S., & Hossian, M. (2025). Cardiovascular complications in patients with hepatocellular carcinoma. Journal of Angiotherapy, 9(1), 1–8. https://doi.org/10.25163/angiotherapy.9110218

Yan, L. (2014). Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. Journal of Diabetes Research, 2014, 1–11. https://doi.org/10.1155/2014/137919

Zhang, S., Meng, Y., Zhou, L., Qiu, L., Wang, H., Su, D., Zhang, B., Chan, K., & Han, J. (2022). Targeting epigenetic regulators for inflammation: Mechanisms and intervention therapy. MedComm, 3(4). https://doi.org/10.1002/mco2.173

Arnold, R., Issar, T., Krishnan, A. V., & Pussell, B. A. (2016). Neurological complications in chronic kidney disease. JRSM Cardiovascular Disease, 5. https://doi.org/10.1177/2048004016677687

Beasley, P. R. (2006b). Diabetes and hepatocellular carcinoma. Hepatology, 44(6), 1408–1410. https://doi.org/10.1002/hep.21430

Harding, J. L., Weber, M. B., & Shaw, J. E. (2024). The Global Burden of Diabetes. Textbook of Diabetes, 28–40. https://doi.org/10.1002/9781119697473.ch3

Li, X., Wang, X., & Gao, P. (2017c). Diabetes mellitus and risk of hepatocellular carcinoma. BioMed Research International, 2017, 1–10. https://doi.org/10.1155/2017/5202684

Mekala, K. C., & Bertoni, A. G. (2019). Epidemiology of diabetes mellitus. In Elsevier eBooks (pp. 49–58). https://doi.org/10.1016/b978-0-12-814833-4.00004-6

Ozakyol, A. (2017). Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). Journal of Gastrointestinal Cancer, 48(3), 238–240. https://doi.org/10.1007/s12029-017-9959-0

Yan, L. (2014). Pathogenesis of chronic hyperglycemia: From reductive stress to oxidative stress. Journal of Diabetes Research, 2014, 1–11. https://doi.org/10.1155/2014/137919

Export Citation

View Dimensions

View Plumx

View Altmetric

0
Save

0
Citation

79
View

0
Share